XML 145 R72.htm IDEA: XBRL DOCUMENT
v3.22.4

Segmentation of key figures (Details 2) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of operating segments [line items] |  |  |
Interest income | $ 379 | $ 71 | $ 91
Impairment charges and fair value gains on financial assets, net | (260) | 38 | 335
Equity-based compensation of Novartis equity plans | (1,048) | (979) | (958)
Restructuring provision [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Additions to restructuring provisions | (1,368) | (328) | (354)
Right-of-use assets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (300) | (318) | (330)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (3) |  |
Intangible assets and goodwill [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (3,982) | (3,903) | (3,462)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (1,326) | (403) | (914)
Property, plant and equipment [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (1,163) | (1,208) | (1,318)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (407) | (281) | (440)
Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Impairment charges and fair value gains on financial assets, net | (134) | 43 | 153
Equity-based compensation of Novartis equity plans | (706) | (721) | (714)
Innovative Medicines | Restructuring provision [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Additions to restructuring provisions | (1,069) | (240) | (217)
Innovative Medicines | Right-of-use assets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (252) | (265) | (273)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (3) |  |
Innovative Medicines | Intangible assets and goodwill [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (3,728) | (3,638) | (3,080)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (1,299) | (367) | (768)
Innovative Medicines | Property, plant and equipment [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (837) | (859) | (912)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (407) | (271) | (324)
Sandoz |  |  |
Disclosure of operating segments [line items] |  |  |
Equity-based compensation of Novartis equity plans | (62) | (65) | (64)
Sandoz | Restructuring provision [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Additions to restructuring provisions | (40) | (62) | (98)
Sandoz | Right-of-use assets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (33) | (39) | (41)
Sandoz | Intangible assets and goodwill [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (222) | (238) | (370)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (25) | (28) | (141)
Sandoz | Property, plant and equipment [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (204) | (210) | (282)
Impairment loss (reversal of impairment loss) recognised in profit or loss |  | (9) | (116)
Corporate |  |  |
Disclosure of operating segments [line items] |  |  |
Impairment charges and fair value gains on financial assets, net | (126) | (5) | 182
Equity-based compensation of Novartis equity plans | (280) | (193) | (180)
Corporate | Restructuring provision [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Additions to restructuring provisions | (259) | (26) | (39)
Corporate | Right-of-use assets [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (15) | (14) | (16)
Corporate | Intangible assets and goodwill [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | (32) | (27) | (12)
Impairment loss (reversal of impairment loss) recognised in profit or loss | (2) | (8) | (5)
Corporate | Property, plant and equipment [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Depreciation and amortisation expense | $ (122) | (139) | $ (124)
Impairment loss (reversal of impairment loss) recognised in profit or loss |  | $ (1) |

X
- Definition The amount of additional other provisions made. [Refer: Other provisions] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 37 -IssueDate 2022-03-24 -Paragraph 84 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_b&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_AdditionalProvisionsOtherProvisions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 28 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B13 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 23 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard -URIDate 2022-03-24 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard -URIDate 2022-03-24 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 99 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard -URIDate 2022-03-24 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 104 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DepreciationAndAmortisationExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 99 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of income arising from interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 23 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 28 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B13 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B -URIDate 2022-03-24 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueFromInterest
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |